Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Drug Delivery Devices

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1797334

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1797334

Infused Drugs

PUBLISHED:
PAGES: 285 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Infused Drugs Market to Reach US$11.8 Billion by 2030

The global market for Infused Drugs estimated at US$8.2 Billion in the year 2024, is expected to reach US$11.8 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Small Molecules Drug, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$7.6 Billion by the end of the analysis period. Growth in the Biologics Drug segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.2 Billion While China is Forecast to Grow at 10.0% CAGR

The Infused Drugs market in the U.S. is estimated at US$2.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 10.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Infused Drugs Market - Key Trends & Drivers Summarized

Why Are Infused Drugs Gaining Preference Across Therapeutic Areas?

Infused drugs, administered directly into the bloodstream or tissue via intravenous or subcutaneous routes, are essential in managing conditions that require rapid, precise, or long-duration dosing. These drugs are widely used in oncology, autoimmune diseases, rare disorders, and chronic infections where oral or topical treatments are inadequate. Infusion allows for controlled bioavailability and bypasses issues related to poor gastrointestinal absorption or patient non-compliance.

Advances in biologics and targeted therapies have expanded the role of infused drugs in treating conditions such as rheumatoid arthritis, multiple sclerosis, and cancer. Infused monoclonal antibodies, immunotherapies, and enzyme replacement therapies are providing highly specific, disease-modifying treatment options. As personalized medicine becomes more prevalent, infused drugs are being tailored based on genetic and biomarker profiles, improving therapeutic precision and outcomes in complex disease areas.

How Are Delivery Systems and Care Settings Evolving?

The administration of infused drugs is shifting beyond hospitals to outpatient clinics, home care, and specialized infusion centers. Portable infusion pumps and simplified infusion kits are enabling greater flexibility and comfort for patients requiring long-term treatment. Home infusion services are expanding, particularly for chronic conditions that need recurrent dosing, supported by remote monitoring and nurse-assisted administration.

Drug delivery systems are also advancing with smart pumps, closed-system transfer devices, and formulations that allow extended infusion intervals. These innovations reduce infection risks, increase patient safety, and improve adherence. Biosimilar versions of infused biologics are being introduced to reduce treatment costs and improve access in both high-income and emerging markets. Formulation technologies are also being optimized to shorten infusion times and reduce infusion-related reactions.

Where Is Market Demand Increasing, and Who Are the Main End-Users?

Oncology remains the largest segment for infused drugs, accounting for a substantial share of global demand due to the rise in cancer incidence and expanded use of targeted therapies. Autoimmune diseases such as Crohn’s disease, psoriasis, and systemic lupus are also major contributors to infusion drug usage. Hospital pharmacies, outpatient infusion clinics, and specialty care centers are the primary settings for administration.

Demand is increasing in both developed and developing countries. North America leads in utilization due to the presence of specialized treatment facilities and reimbursement frameworks. Europe follows with strong adoption of biosimilars and home-based infusion models. Asia Pacific is experiencing growth due to rising healthcare access, cancer screening programs, and government-backed chronic care initiatives. Infusion drug demand is also supported by transplant care, infectious disease management, and rare metabolic disorders.

What Is Driving Growth in the Infused Drugs Market?

Growth in the infused drugs market is driven by several factors including increasing incidence of chronic and rare diseases, advances in biologic therapies, and rising adoption of outpatient and home-based infusion services. Technological improvements in delivery systems, including portable and programmable infusion devices, are supporting safer and more convenient treatment settings. Demand is also supported by expanding indications for infused immunotherapies and long-acting biologics across autoimmune and oncology domains.

End-use expansion in ambulatory care, specialty clinics, and home infusion programs is increasing treatment accessibility while reducing the cost burden of inpatient administration. Development of biosimilars and payer initiatives to support home infusions are creating cost-effective treatment pathways. The growing role of precision medicine and companion diagnostics is strengthening demand for high-efficacy infused drugs with targeted mechanisms of action. These trends are collectively reinforcing the global market for infused therapies across multiple disease areas and care models.

SCOPE OF STUDY:

The report analyzes the Infused Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Small Molecules Drug, Biologics Drug); Therapeutic Area (Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Diabetes Therapeutic Area, Other Therapeutic Areas)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • Amneal Pharmaceuticals Inc.
  • Apotex Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • Hikma Pharmaceuticals plc
  • Parenteral Drugs (India) Ltd.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Stada Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd.
  • Weefsel Pharma (Weefsel Biopharma)
  • Wockhardt Ltd.
  • Zydus Cadila

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP38949

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Infused Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic and Autoimmune Diseases Drives Demand for Long-Term Administration of Infused Therapies
    • Expansion of Biologic Drug Development Pipelines Strengthens Growth in IV-Delivered Monoclonal Antibodies and Targeted Treatments
    • OEM Innovation in Formulation Stability and Infusion Device Compatibility Enhances Safety and Efficacy of Infused Medications
    • Growing Shift Toward Outpatient and Home Infusion Models Throws Spotlight on Portable and Self-Administered Infusion Systems
    • Surge in Cancer Treatment Protocols Involving Chemotherapy and Immunotherapy Supports Use of Infused Drug Regimens
    • OEM Focus on Closed-System Drug Transfer Devices and Catheter Safety Enhances Risk Management During Infusion Procedures
    • Increasing Role of Specialty Pharmacies and Infusion Clinics Promotes Access to High-Cost Infused Therapies
    • Expansion of Value-Based Care Models Drives Emphasis on Cost-Effectiveness and Outcome Monitoring for Infused Drugs
    • OEM Integration of Infusion Monitoring Software With EHR Systems Improves Documentation and Clinical Oversight
    • Rising Demand for Personalized Dosing and Weight-Based Infusion Protocols Supports Precision Medicine Approaches
    • Growth in Pediatric and Rare Disease Therapies Fuels Innovation in Low-Volume, High-Potency Infused Drug Formats
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Infused Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Infused Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Infused Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Infused Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Small Molecules Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Small Molecules Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Small Molecules Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biologics Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Biologics Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Biologics Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Oncology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Oncology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Oncology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Gastrointestinal Diseases Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Gastrointestinal Diseases Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Gastrointestinal Diseases Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Rheumatoid Arthritis Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Rheumatoid Arthritis Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Immune Deficiencies Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Immune Deficiencies Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Immune Deficiencies Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cardiology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Cardiology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Cardiology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Neurology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Neurology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Neurology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Diabetes Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Diabetes Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Diabetes Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • JAPAN
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • CHINA
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: China 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: China 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • EUROPE
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Infused Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Infused Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Infused Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • FRANCE
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: France 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 71: France Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: France 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • GERMANY
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Germany 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Italy 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 86: UK Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 89: UK Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: UK 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 95: Spain Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Spain 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 101: Russia Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Russia 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Rest of Europe 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Infused Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Infused Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Infused Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Asia-Pacific 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 122: Australia Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Australia 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • INDIA
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 125: India Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: India 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 128: India Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: India Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: India 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: South Korea 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Infused Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Infused Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Infused Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Latin America 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Argentina 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Brazil 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Mexico 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Rest of Latin America 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Infused Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Infused Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Infused Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Middle East 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 188: Iran Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Iran 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 194: Israel Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Israel 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Saudi Arabia 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 206: UAE Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: UAE 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Rest of Middle East 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • AFRICA
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 218: Africa Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Africa 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!